Premium
Immune response to recombinant Leishmania infantum lipophosphoglycan 3 plus CpG oligodeoxynucleotides in BALB /c mice
Author(s) -
Pirdel L.,
Zavaran Hosseini A.
Publication year - 2017
Publication title -
parasite immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.795
H-Index - 75
eISSN - 1365-3024
pISSN - 0141-9838
DOI - 10.1111/pim.12345
Subject(s) - cpg oligodeoxynucleotide , lipophosphoglycan , leishmania infantum , immune system , adjuvant , biology , immunology , leishmania , balb/c , immunization , vaccination , virology , leishmaniasis , visceral leishmaniasis , leishmania donovani , parasite hosting , biochemistry , gene expression , gene , world wide web , dna methylation , computer science
Summary Development of a protective antileishmanial vaccine is an urgent priority for successful control of different forms of leishmaniasis. The potential of a recombinant lipophosphoglycan 3 ( rLPG 3) expressed by Leishmania tarentolae was evaluated in combination with CpG oligodeoxynucleotides (CpG‐ ODN ) as a Th1‐promoting adjuvant against Leishmania infantum infection in BALB /c mice. First, mice were immunized subcutaneously with rLPG 3 either alone or in combination with CpG‐ ODN . Next, the immunogenic and protective efficacies of this vaccine were analysed in immunized mice. It was observed that coadministration of rLPG 3 with CpG‐ ODN led to enhance in a Th1 response to rLPG 3 induced by itself as the IFN ‐γ production was promoted in association with the predominant presence of IgG2a antibodies in the sera. However, immunization with rLPG 3 plus CpG‐ ODN induced partial protection against infectious challenge in BALB /c mice. Taken together, further studies are required to improve the protective efficacy using either more potent immune enhancers or vaccination strategies.